ClinicalTrials.Veeva

Menu

Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer

G

Gunma University

Status

Completed

Conditions

Carcinoma, Non-Small-Cell Lung

Study type

Observational

Funder types

Other

Identifiers

NCT00464282
Gunma 444

Details and patient eligibility

About

Objective: L-[3-18F]-α-methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients. Tumor uptake of 18F-FMT PET was compared with 18F-FDG PET and the correlation with L-type amino acid transporter 1 (LAT1) expression also investigated.

Method: Fifty patients with NSCLC were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.

Sex

All

Ages

8 months to 2 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • proven or suspected non-small cell lung cancer

Exclusion criteria

  • uncontrolled diabetes mellitus

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems